Relapsed Acute Lymphoblastic Leukemia (ALL) Not Yet Recruiting Phase 1 / 2 Trials for Ruxolitinib (DB08877)

Back to Relapsed Acute Lymphoblastic Leukemia (ALL)

Also known as: Acute Lymphoblastic Leukemia, in Relapse / Relapsed ALL / Relapsed Acute Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia

Indication	Status	Phase
DBCOND0069491 (Relapsed Acute Lymphoblastic Leukemia (ALL))	Not Yet Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05745714	HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies	Treatment	Cyclophosphamide (DB00531) Cytarabine (DB00987) Dexamethasone (DB01234) Ruxolitinib (DB08877) Venetoclax (DB11581)